Acumen Pharmaceuticals, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.acumenpharm.com

Safety Score

Market Cap $136.33M
PE -2
Debt $29.67M
Cash $33.42M
EV $132.58M
FCF -$67.34M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$81.67M
EBIT	-$92.91M
ROE	-38%
ROA	-35%
FCF	-$67.34M
Equity	$217.20M
Growth Stability	1
PE	-1.67
PB	0.63
P/FCF	-2.02
Price/Cash	0.25
Debt/Equity	0.14
Debt/FCF	-0.44
Equity CAGR	4%
Earnings Growth YoY	130%
Earnings Growth QoQ	45%

Equity CAGR 5Y	4%
Equity CAGR 3Y	7%
Market Cap	$136.33M
Assets	$266.98M
Total Debt	$29.67M
Cash	$33.42M
Shares Outstanding	59.79M
EV	132.58M
Safety Score	65%
Working Capital	187.72M
Current Ratio	10.43
Shares Growth 3y	18%
Equity Growth QoQ	-11%
Equity Growth YoY	-23%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

SEC Filings

Direct access to Acumen Pharmaceuticals, Inc. (ABOS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Acumen Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Acumen Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Acumen Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Acumen Pharmaceuticals, Inc..

Years

Calculation mode

= -$673M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$67M	-$67M	-$67M	-$67M	-$67M	-$67M	-$67M	-$67M	-$67M	-$67M	-$67M	-$673M
DCF		-$61M	-$56M	-$51M	-$46M	-$42M	-$38M	-$35M	-$31M	-$29M	-$26M	-$260M
Value	-$673M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-
ROA	-	-9%	-23%	-20%	-35%
ROE	-	-45%	-23%	-20%	-38%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-0	-0.69	-0.44
Debt over Equity	-	-	0	0.11	0.14
Growth Stability	-	-	-	-	1

Good Debt/FCF ratio (-0.44)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.14)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-
Earnings YoY growth	-	1K%	-57%	22%	-
Equity YoY growth	-	-1K%	-16%	41%	4%
FCF YoY growth	-	-	96%	22%	-